Abstract
Background Deciphering the function of the many genes previously classified as uncharacterized “open reading frame” (orf) completes our understanding of cell function and its pathophysiology.
Methods Whole-exome sequencing, yeast 2-hybrid and transcriptome analyses together with molecular characterization are used here to uncover the function of the C2orf69 gene.
Results We identify loss-of-function mutations in the uncharacterized C2orf69 gene in eight individuals with brain abnormalities involving hypomyelination and microcephaly, liver dysfunction and recurrent autoinflammation. C2orf69 contains an N-terminal signal peptide that is required and sufficient for mitochondrial localization. Consistent with mitochondrial dysfunction, patients show signs of respiratory chain defect and a CRISPR-Cas9 knockout cell model of C2orf69 shows comparable respiratory chain defects. Patient-derived cells reveal alterations in immunological signaling pathways. Deposits of PAS-positive material in tissues from affected individuals together with decreased glycogen branching enzyme 1 (GBE1) activity indicate an additional impact of C2orf69 on glycogen metabolism.
Conclusion Our study identifies C2orf69 as an important regulator of human mitochondrial function and suggests an additional influence on other metabolic pathways.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Deutsche Forschungsgemeinschaft (DFG) and Fund Invest for Scientific Research (FIRS) Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from the parents / legal guardians of the study participants after approval from the Institutional Review Boards at the participating institutions (EK302-16; UK D 4886R; H12-00067, UBC). Consent was obtained according to the Declaration of Helsinki. EK302-16 approved by Ethik-Kommission an der Medizinischen Fakultaet der Rheinisch-Westfaelischen Technischen Hochschule Aachen (RWTH Aachen) Universitaetsklinikum Aachen Pauwelsstrasse 30 52074 Aachen ekaachen{at}ukaachen.de https://www.medizin.rwth-aachen.de/cms/Medizin/Die-Fakultaet/Organisation/~coeq/Ethik-Kommission/ UK D 4886R approved by Ethikkommission an der Med. Fakultaet der HHU Duesseldorf Gebaeude 14.82.01 Moorenstr. 5 40225 Duesseldorf ethikkommission{at}med.uni-duesseldorf.de https://www.medizin.hhu.de/dekanat/gremien-und-kommissionen/kommissionen/ethikkommission.html H12-00067 approved by UBC Clinical Research Ethics Office Room 210, Research Pavilion 828 West 10th Avenue Vancouver, BC Canada V5Z 1L8 pia.ganz{at}ors.ubc.ca https://ethics.research.ubc.ca/clinical-research-ethics
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† shared last authors
The authors have declared that no conflict of interest exists.
Data Availability
data is avaiable upon request, if not protected by GDPR